Comments
Jubilant Life Sciences has received approval from the US regulator for Irbesartan and Cetirizine Hydrochloride tablets used for treatment of hypertension and allergies respectively. It has received final nod from the US FDA for its abbreviated new drug application. The total market size for Irbesartan tablets is about $50 million/annum. The stock jumped sharply on Tuesday itself though the announcement came to the exchanges only after market hours.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.